Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSB-001 in Limbal Stem Cell Deficiency
NCT06452316Phase 1Recruiting
- Sponsor
- Claris Bio
- Start
- May 2024
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dHGF in limbal stem cell deficiency (LSCD) (2 arms), sponsored by Claris Bio. Primary endpoints: Adverse Events, Safety as Assessed by Slit-lamp Biomicroscopy and 1 more. Started May 2024; status: recruiting.
02
Drugs
dHGF
03
Conditions
limbal stem cell deficiency (LSCD)
Beyond the preview
Go deeper on NCT06452316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452316.